Department of Health and Human Services
National Institutes of Health
Toggle navigation
Search
Home
About the Clinical Center
Clinical Trials & You
Participate in a Study
Referring a Patient
How to Search
Contact Us
Search the Studies
Go Back
Searched Result
202 Studies found from all possible combinations of your search terms. Select a protocol that you wish to review.
Protocol Number
Title
Protocol Status
Min-Max Age
Institute
Keywords
001109-C
Defining the Natural History of Squamous Cell Carcinoma in Fanconi Anemia
Participants currently recruited/enrolled
8-125 Years
NCI
Liver Carcinoma
000826-C
An Open Label, Randomised, Phase 2 Study to Evaluate the Safety and Efficacy of MTL-CEBPA Administered in Combination with Sorafenib or Sorafenib Alone, in TKI Naive Participants with Previously Treated Advanced Hepatocellular Carcinoma (HCC) and Hepatit
Recruitment has not started
18-125 Years
NCI
Liver Carcinoma
000491-C
Tissue Procurement and Natural History Study of Neuroendocrine Neoplasms (NENs) Including Adrenocortical Carcinoma (ACC)
Participants currently recruited/enrolled
18-125 Years
NCI
Liver Carcinoma
000473-C
A Randomized Phase II Study of Systemic Chemotherapy with or without HAI FUDR-Dexamethasone in Patients with Unresectable Intrahepatic Cholangiocarcinoma
Participants currently recruited/enrolled
18-125 Years
NCI
Liver Carcinoma
000080-C
18F-DCFPyL PET/CT in Hepatocellular Carcinoma
Participants currently recruited/enrolled
18-125 Years
NCI
Liver Carcinoma
21-C-0030
Phase I Study of GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Hepatocellular Carcinoma (HCC)
Participants currently recruited/enrolled
18-125 Years
NCI
Liver Carcinoma
20-CC-0039
A Feasibility Study to Evaluate the Combination of Electromagnetic Tracking and Optical Imaging with Indocyanine Green (ICG) for Hepatic Biopsies
Enrolling by Invitation
18-125 Years
CC
Liver Carcinoma
20-C-0152
Phase II Study of combination of Trametinib (MEK inhibitor) and Hydroxychloroquine (HCQ) (autophagy inhibitor) in Patients with KRAS Mutation Refractory Bile Tract Carcinoma (BTC).
Participants currently recruited/enrolled
18-125 Years
NCI
Liver Carcinoma
20-C-0022
Phase II trial of VB-111 in Combination with Nivolumab in Patients with Metastatic Colorectal Cancer (mCRC)
Completed Study; data analyses ongoing
18-125 Years
NCI
Liver Carcinoma
20-C-0006
A National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer (PLC)
Participants currently recruited/enrolled
18-125 Years
NCI
Liver Carcinoma
19-C-0094
A Phase II Study of Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects with Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinoma (BTC)
Participants currently recruited/enrolled
18-125 Years
NCI
Liver Carcinoma
19-C-0039
Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers
Completed Study; data analyses ongoing
18-125 Years
NCI
Liver Carcinoma
19-C-0033
Phase II Study of Nivolumab (anti-PD1), Tadalafil and Oral Vancomycin in Patients with Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer from Colorectal or Pancreatic Cancers
Completed Study; data analyses ongoing
18-125 Years
NCI
Liver Carcinoma
18-DK-0091
Long-Term Follow-Up Of Subjects With CHC Who Achieved A Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents
Participants currently recruited/enrolled
18-125 Years
NIDDK
Liver Carcinoma
18-C-0024
A Single-Arm Phase II Study of Hepatic Artery Infusion Pump Chemotherapy with Floxuridine and Dexamethasone in Combination with Systemic Chemotherapy for Patients with Colorectal Cancer Metastatic to the Liver
Participants currently recruited/enrolled
18-125 Years
NCI
Liver Carcinoma
16-C-0154
A Phase I/II Trial of T Cell Receptor Gene Therapy Targeting HPV-16 E7 for HPV-Associated Cancers
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma Situ
16-C-0135
A Pilot Study of Combined Immune Checkpoint Inhibition in combination with Ablative Therapies in Subjects with Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)
No longer recruiting/follow-up only
18-125 Years
NCI
Liver Carcinoma
11-CC-0152
The Natural History of Liver Disease in a Cohort of Participants with Hepatitis B and/or Hepatitis C with or without HIV Infection
Completed Study; data analyses ongoing
18-99 Years
CC
Liver Carcinoma
05-CC-0091
Electromagnetic Tracking of Devices During Interventional Procedures
Enrolling by Invitation
18-125 Years
CC
Liver Carcinoma
89-C-0086
Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders
Participants currently recruited/enrolled
2-125 Years
NCI
Carcinoma Situ
001125-DK
Optimizing HBV Care Cascade among Foreign-Born in the United States (FOCUS-HBV Study)
Participants currently recruited/enrolled
18-100 Years
NIDDK
Liver
001124-I
Expanded Access IND Protocol: Use of Tecovirimat (TPOXX (R)) for Treatment of Human Non-Variola Orthopoxvirus Infections in Adults and Children
Enrolling by Invitation
0-125 Years
NIAID
Situ
001099-C
A Phase 1/2, First-in-Human, Open-Label, Dose Escalation and Expansion Study of STAR0602, a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-Fusion Molecule, in Subjects with Unresectable, Locally Advanced, or Metastatic Solid Tumors that
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
001032-C
BAY 1895344 Plus Topoisomerase-1 (Top1) Inhibitors in Patients with Advanced Solid Tumors, Phase I Studies with Expansion Cohorts in Small Cell Lung Carcinoma (SCLC), Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) and Pancreatic Adenocarcinoma (
Recruitment has not started
18-125 Years
NCI
Carcinoma
001018-CH
Establishment of Genomic and Phenotypic Database for Niemann-Pick Disease, Type C
Participants currently recruited/enrolled
0-125 Years
NICHD
Liver
001004-C
A Phase 1b/2 Basket Study of ACR-368 as Monotherapy and in Combination with Gemcitabine in Adult Subjects with Platinum-Resistant Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma Based on Acrivon Oncosignature (R) Status
Participants currently recruited/enrolled
18-120 Years
NCI
Carcinoma
000958-C
Prospective Procurement of Tumor Tissue to Identify Novel Therapeutic Targets and Study the Tumor Microenvironment
Enrolling by Invitation
18-125 Years
NCI
Liver
000957-HG
A Phase 1/2, Open-Label, Single Dose Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of SEL-302 (MMA-101 following administration of SEL-110) in Pediatric Subjects with Mut Subtype Isolated Methylmalonic Acidemia (MMA)
Participants currently recruited/enrolled
3-17 Years
NHGRI
Liver
000930-C
A Phase 1b/2 Study of HCW9218, a Bifunctional TGF-Beta Antagonist/IL-15 Protein Complex, for Advanced Pancreatic Cancer
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
000784-N
Assessing and Improving Quantitative Magnetic Resonance Imaging Metrics in Human Subjects
Participants currently recruited/enrolled
18-125 Years
NINDS
Liver
000782-C
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors
Recruitment has not started
18-125 Years
NCI
Carcinoma
000686-CH
Intrathecal 2-Hydroxypropyl-Beta-Cyclodextrin for Neurological Decline in Patients with Niemann-Pick Disease Type C1
Participants currently recruited/enrolled
18-125 Years
NICHD
Liver
000666-C
A Phase I/II Study of Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)
Recruitment has not started
18-125 Years
NCI
Carcinoma
000665-DK
A Randomized Double-Blind Placebo-Controlled Study of the LEPR Agonist Antibody REGN4461 for the Treatment of Metabolic Abnormalities in Patients with Familial Partial Lipodystrophy
Participants currently recruited/enrolled
18-125 Years
NIDDK
Liver
000596-C
Phase II Study of Olaparib in Subjects with Advanced Pancreatic Acinar Cell Carcinoma
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
000580-C
A Phase 1/2, Open Label Dose-Escalation and Expansion Trial of Nkt2152, an Orally Administered Hif2a Inhibitor, to Investigate Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity in Patients with Advanced Clear Cell Renal Cell Carcinoma
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
000545-DK
Prevalence and Development of Liver Dysfunction in Hematopoietic Stem Cell Transplant: A Prospective Natural History Study
Recruitment has not started
3-125 Years
NIDDK
Liver
000520-C
Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG with or without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer
Recruitment has not started
18-125 Years
NCI
Carcinoma
000494-DK
Natural History of Fontan Associated Liver Disease and the Evaluation of Biomarkers for Disease Severity Assessment
Participants currently recruited/enrolled
18-125 Years
NIDDK
Liver
000486-C
A Phase 1 Trial of the ATR Inhibitor BAY 1895344 in Combination with Cisplatin and with Cisplatin Plus Gemcitabine in Advanced Solid Tumors with an Emphasis on Urothelial Carcinoma
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
000479-H
Observational Study to Deeply Phenotype Major Organs in Sickle Cell Disease After Curative Therapies
Participants currently recruited/enrolled
18-125 Years
NHLBI
Liver
000462-C
Phase 2, Open-label, Single-arm, Window of Opportunity Study of ASP-1929 Photoimmunotherapy with Fluorescence Imaging in Patients With Operable Primary or Recurrent Head and Neck or Cutaneous Squamous Cell Carcinoma
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
000387-H
The Natural History of Acquired and Inherited Bone Marrow Failure Syndromes.
Participants currently recruited/enrolled
2-125 Years
NHLBI
Liver
000354-C
Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
000317-C
A Phase II, Open-Label Trial of PT-112 in Subjects with Thymoma and Thymic Carcinoma
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
000307-C
Phase II Study Evaluating the Efficacy of M9241 in Combination with Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects with Metastatic Colorectal Cancer or Intrahepatic Cholangiocarcinoma
Participants currently recruited/enrolled
18-125 Years
NCI
Liver
000302-C
A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract Malignancies
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
000254-C
A Phase II Trial of the Superenhancer Inhibitor Minnelide in Advanced Refractory Adenosquamous Carcinoma of the Pancreas (ASCP)
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
000237-C
Phase II Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis from Colorectal, Appendiceal, Small Bowel, Gastric, Ovarian, or Other Gynecologic Primary Cancer
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
000236-I
A Phase 1 Study of Empagliflozin as Treatment for Severe Congenital Neutropenia Due to G6PC3 Deficiency
Participants currently recruited/enrolled
18-125 Years
NIAID
Liver
000137-CH
Implications of Maternal 45,X Mosaicism As A Secondary Genomic Finding Following Cell-free DNA Sequencing During Pregnancy: A Deep Phenotype Study
Recruitment has not started
18-99 Years
NICHD
Liver
000130-DK
Unraveling the Mechanisms Underlying Primary Sclerosing Cholangitis Through a Multidisciplinary, Integrative Research Approach
Participants currently recruited/enrolled
18-125 Years
NIDDK
Liver
000118-DK
Prospective Cohort Study to Determine the Response to COVID-19 Vaccination and Prevalence of COVID-19 in Subjects with Chronic Liver Disease
Participants currently recruited/enrolled
18-100 Years
NIDDK
Liver
000079-DK
The Role of 68-Gallium-DOTATATE-PET/CT in the Imaging of Metastatic Thyroid Cancer
Participants currently recruited/enrolled
18-125 Years
NIDDK
Liver
000077-DC
Collection of Clinical Data and Specimens for Research on Head and Neck and Communication Disorders
Participants currently recruited/enrolled
2-125 Years
NIDCD
Carcinoma
000045-C
A Phase I Trial of T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and other KK-LC-1 Positive Epithelial Cancers
Participants currently recruited/enrolled
18-120 Years
NCI
Carcinoma
000036-AA
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Study of Safety, Tolerability, and Bioeffects of Alirocumab in Non-treatment Seeking Heavy Drinkers
Participants currently recruited/enrolled
21-65 Years
NIAAA
Liver
22-C-0005
Phase I Dose Escalation and Expansion Study of Tazemetostat in Combination with Topotecan and Pembrolizumab in Recurrent Small Cell Lung Cancer
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
22-C-0004
A Phase II Study of Bevacizumab, Erlotinib and Atezolizumab in Subjects with Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) Associated or Sporadic Papillary Renal Cell Cancer
Participants currently recruited/enrolled
12-125 Years
NCI
Carcinoma
21-DC-0002
Phase III Interventional Study using Atorvastatin to Reduce Cisplatin-Induced Hearing Loss among Individuals with Head and Neck Cancer
Recruitment has not started
18-125 Years
NIDCD
Carcinoma
21-C-0023
A Phase I Study of Pomalidomide and Nivolumab in Patients with Virus-Associated Malignancies With or Without HIV
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
21-C-0012
Individualized Response Assessment to Heated Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Peritoneal Carcinomatosis from Ovarian, Colorectal, Appendiceal, or Peritoneal Mesothelioma Histologies
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
20-H-0141
Long-term Follow-up of Subjects With Sickle Cell Disease Treated With Ex Vivo Gene Therapy Using Autologous Hematopoietic Stem Cells Transduced With a Lentiviral Vector
Enrolling by Invitation
18-125 Years
NHLBI
Liver
20-H-0021
Treatment of Refractory Diamond-Blackfan Anemia with Eltrombopag
No longer recruiting/follow-up only
2-125 Years
NHLBI
Liver
20-DK-0079
A Randomized, Double-Blinded, Placebo-Controlled Study of REGN4661, A Leptin Receptor Agonist Antibody, In Patients with Generalized Lipodystrophy
No longer recruiting/follow-up only
12-125 Years
NIDDK
Liver
20-DK-0067
A Phase 3, Matrix Design, Partially Double-Blind, Randomized Study of the Efficacy and Safety of 50 mg Lonafarnib/100 mg Ritonavir BID with and without 180 mcg PEG IFN-alfa-2a for 48 Weeks Compared with PEG IFN-alfa-2a Monotherapy and Placebo Treatment i
No longer recruiting/follow-up only
18-125 Years
NIDDK
Liver
20-CH-0165
Androgen Receptor, Implications for Health and Wellbeing: Natural History Study of Individuals with Androgen Insensitivity
Participants currently recruited/enrolled
0-99 Years
NICHD
Liver
20-C-0162
A Phase 1 Study of Venetoclax with Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies
Participants currently recruited/enrolled
18-125 Years
NCI
Liver
20-C-0149
Phase II Trial of Olaparib (LYNPARZA) plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas that Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
20-C-0142
A Phase II Study of Bintrafusp alfa (M7824) in Checkpoint Inhibitor Naive and Refractory Subjects with Urothelial Carcinoma
Completed Study; data analyses ongoing
18-125 Years
NCI
Carcinoma
20-C-0098
A Phase 1/2, Open Label, Dose-Escalation, Safety and Tolerability Study of NC410 in Subjects with Advanced or Metastatic Solid Tumors
Completed Study; data analyses ongoing
18-125 Years
NCI
Carcinoma
20-C-0097
A Phase II, Open-Label Trial of Bintrafusp Alfa (M7824) in Subjects with Thymoma and Thymic Carcinoma
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
20-C-0028
Phase 1/2 Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults with Relapsed/Refractory Acute Myeloid Leukemia
Participants currently recruited/enrolled
3-35 Years
NCI
Liver
20-C-0024
A Sequential Window of Opportunity Trial of Anti-PD-L1/TGF-beta trap (M7824 ) Alone and in Combination with TriAd Vaccine, and N-803 for Resectable Head and Neck Squamous Cell Carcinoma not Associated with Human Papillomavirus Infection.
No longer recruiting/follow-up only
18-125 Years
NCI
Carcinoma
20-C-0013
Phase I/II Trial of PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers
No longer recruiting/follow-up only
18-125 Years
NCI
Carcinoma
20-C-0012
A Phase I Study of Bintrafusp alfa (M7824) and NHS-IL12 (M9241) Alone and in Combination with Stereotactic Body Radiation Therapy (SBRT) in Adults with Metastatic Non-Prostate Genitourinary Malignancies
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
20-C-0009
Randomized Phase II Trial of Topotecan Plus M6620 (VX-970) vs. Topotecan Alone in Patients with Relapsed Small-Cell Lung Cancer
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
19-I-0140
A Phase 1 Evaluation of the Safety of Belimumab in People with Idiopathic CD4 Lymphopenia and Autoantibodies (Phoebe)
Participants currently recruited/enrolled
18-70 Years
NIAID
Situ
19-H-0139
Investigation of the Natural Progression of Clonal Hematopoiesis of Indeterminate Potential and Clonal Cytopenia of Undetermined Significance.
Participants currently recruited/enrolled
18-125 Years
NHLBI
Liver
19-H-0057
Multiple Patient Program for Lamprene (clofazimine) for the treatment of Non-Tuberculous Mycobacterial (NTM) Infections- CLAM320B2002M
Participants currently recruited/enrolled
18-99 Years
NHLBI
Liver
19-DK-0072
Non-Alcoholic Fatty Liver Disease, the Hepatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
Participants currently recruited/enrolled
18-125 Years
NIDDK
Liver
19-DK-0067
Effect of Low Fat versus Low Carbohydrate Diets on Energy Metabolism
Completed Study; data analyses ongoing
18-50 Years
NIDDK
Liver
19-CH-0071
An Open-Label Phase 3 Study of the Safety and Efficacy of Pegvisomant in Children with Growth Hormone Excess
Participants currently recruited/enrolled
2-18 Years
NICHD
Liver
19-C-0137
A Phase II Study of Ipilimumab, Cabozantinib, and NIvolumab in Rare Genitourinary Cancers (ICONIC)
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
19-C-0134
A Phase 1/1b Study of Enhancement of Immune Reconstitution and Vaccine Responses with Administration of Recombinant Human IL-7-hyFc (NT-I7) in Older Subjects Following Chemotherapy
Participants currently recruited/enrolled
60-125 Years
NCI
Carcinoma
19-C-0129
A Phase II Study of Intraperitoneal and Intravenous Paclitaxel Chemotherapy with Oral Capecitabine for Gastric Adenocarcinoma with Peritoneal Carcinomatosis
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
19-C-0041
Birinapant and Intensity Modulated Re-Irradiation Therapy (IMRRT) for Locoregionally Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
19-C-0023
A Phase II Study of Olaparib (AZD2281) in Patients with Metastatic/Advanced Urothelial Carcinoma and other genitourinary tumors with DNA-Repair Defects
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
19-C-0016
Natural History and Biospecimen Acquisition Study for Children and Adults with Rare Solid Tumors
Participants currently recruited/enrolled
0-125 Years
NCI
Carcinoma
18-H-0012
A Phase I Study of HERV-E TCR Transduced Autologous T Cells in Patients with Metastatic Clear Cell Renal Cell Carcinoma
Participants currently recruited/enrolled
18-75 Years
NHLBI
Carcinoma
18-H-0004
Low Dose Danazol for the Treatment of Telomere Related Diseases
Participants currently recruited/enrolled
3-125 Years
NHLBI
Liver
18-EI-0068
An Investigation of Vitamin A Palmitate Supplementation in Patients with Reticular Pseudodrusen (RPD) and Delayed Dark Adaptation
Participants currently recruited/enrolled
50-125 Years
NEI
Liver
18-EI-0067
An Investigation of Vitamin A Palmitate Supplementation in Patients with Age-Related Macular Degeneration (and without reticular pseudodrusen) and Delayed Dark Adaptation
Participants currently recruited/enrolled
50-125 Years
NEI
Liver
18-DK-N071
Early Tracking of Childhood Health Determinants Study
Participants currently recruited/enrolled
0-125 Years
NIDDK
Liver
18-DK-0123
Treatment of Chronic Delta Hepatitis with Lonafarnib, Ritonavir and Lambda Interferon
Completed Study; data analyses ongoing
18-125 Years
NIDDK
Liver
18-DA-N053
Imaging Biomarker for Addiction Treatment Outcome
Participants currently recruited/enrolled
21-125 Years
NIDA
Situ
18-C-0147
Phase 1 with Expansion Cohorts in a Study of NEO-201 In Adults with Chemo-Resistant Solid Tumors
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
18-C-0138
An Open-Label Phase 2 Study to Evaluate PT2977 for the Treatment of Von Hippel-Lindau Disease-Associated Renal Cell Carcinoma.
No longer recruiting/follow-up only
18-125 Years
NCI
Carcinoma
18-C-0110
Safety Run-In and Phase II Trial of M7824 and Topotecan or Temozolomide in Relapsed Small Cell Cancers
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
18-C-0062
Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
Completed Study; data analyses ongoing
2-30 Years
NCI
Carcinoma
18-C-0034
A Phase 2 Study of ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma
Completed Study; data analyses ongoing
18-125 Years
NCI
Carcinoma
18-C-0008
Phase III Randomized Adjuvant study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) versus Observation
No longer recruiting/follow-up only
18-125 Years
NCI
Carcinoma
17-DK-0054
The Physiological Responses and Adaptation of Brown Adipose Tissue to Chronic Treatment with Beta3-Adrenergic Receptor Agonists
Participants currently recruited/enrolled
18-40 Years
NIDDK
Liver
17-DK-0013
Therapeutic Targets in African-American Youth with Type 2 Diabetes
Participants currently recruited/enrolled
12-25 Years
NIDDK
Liver
17-DC-0138
Observational Study of Hearing Loss and the Effects of Statin Drugs in Head and Neck Squamous Cell Carcinoma Patients Treated with Cisplatin Chemoradiation
Completed Study; data analyses ongoing
18-125 Years
NIDCD
Carcinoma
17-DA-0093
Exploring Gut-Brain and Brain-Gut Interactions in Alcohol Use Disorder via Microbiota Investigations: A Pilot Study
Completed Study; data analyses ongoing
21-70 Years
NIDA
Liver
17-C-0157
A Phase I Single-Arm Study of the Combination of Durvalumab (MEDI4736) and Vicineum (oportuzumab monatox, VB4-845) in Subjects with High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated with Bacillus Calmette-Gu(SqrRoot)(Copyright)rin (BCG)
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
17-C-0140
Phase I/II Evaluation of Oral Decitabine/Tetrahydrouridine as Epigenetic Priming for Pembrolizumab Immune Checkpoint Blockade in Inoperable Locally Advanced or Metastatic Non-Small Cell Lung Cancers, Esophageal Carcinomas, or Pleural Mesotheliomas
Completed Study; data analyses ongoing
18-99 Years
NCI
Carcinoma
17-C-0117
A Phase 1/2a, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-Tumor Activity of PEN-866 in Advanced Solid Malignancies
Completed Study; data analyses ongoing
18-125 Years
NCI
Carcinoma
17-C-0092
A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination with Immune Checkpoint Inhibition in Refractory Colorectal Cancer
Completed Study; data analyses ongoing
18-125 Years
NCI
Carcinoma
17-C-0086
An Open-label Phase 2 Study to Evaluate PT2385 for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma
No longer recruiting/follow-up only
18-125 Years
NCI
Carcinoma
17-C-0066
A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma after Progression on Platinum-Based Chemotherapy
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
17-C-0048
Anti-CD30 CAR T Cells with Fully-human Binding Domains for Treating CD30-expressing Lymphomas Including Anaplastic Large Cell Lymphomas
Completed Study; data analyses ongoing
18-73 Years
NCI
Liver
17-C-0011
Phase 1 Study of Intraperitoneal Infusion of Autologous Monocytes with Sylatron (Peginterferon alfa-2b) and Actimmune (Interferon gamma-1b) in Women with Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer
Completed Study; data analyses ongoing
18-125 Years
NCI
Carcinoma
16-DK-0143
Idiosyncratic Liver Injury Associated with Drugs (ILIAD): A Retrospective Study
Participants currently recruited/enrolled
18-125 Years
NIDDK
Liver
16-DK-0038
A Randomized, Double Blind, Placebo-Controlled Study to Assess Efficacy, Safety and Tolerability of ISIS 304801 in Patients with Partial Lipodystrophy with an Open-Label Extension
Completed Study; data analyses ongoing
18-125 Years
NIDDK
Liver
16-CC-0049
A Phase II Study Using LC Bead LUMI Radio-Opaque Embolic Beads to Detect and Characterize the Vascularity of Hepatic Tumors During Treatment with Transarterial Embolization (TAE) Alone or Combined with Thermal Ablation
Enrolling by Invitation
18-125 Years
CC
Liver
16-C-0128
A Phase I/II Study of Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination with Nab-Paclitaxel in Participants with Previously Treated Metastatic and/ or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors
Completed Study; data analyses ongoing
18-125 Years
NCI
Carcinoma
16-C-0121
A Pilot Clinical Trial of Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma
Completed Study; data analyses ongoing
18-125 Years
NCI
Carcinoma
16-C-0107
A Phase I/II Trial of EP0057, a Nanoparticle Camptothecin with Olaparib in Patients with Relapsed/Refractory Small Cell Lung, Bladder and Prostate Cancers
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
15-M-0182
Psychological Treatments for Youth with Severe Irritability
Participants currently recruited/enrolled
8-17 Years
NIMH
Situ
15-DK-0174
Dynamic Post-Prandial Metabolism in Patients with Non-Alcoholic Fatty Liver Disease
Completed Study; data analyses ongoing
18-125 Years
NIDDK
Liver
15-DK-0170
Treatment of Chronic Delta Hepatitis with Lonafarnib and Ritonavir
Completed Study; data analyses ongoing
18-99 Years
NIDDK
Liver
15-DK-0143
Investigation of Viral Kinetics, Interferon Stimulated Genes (ISGs) and mirRNA Among Subjects Infected with Different Hepatitis C Virus Genotypes During Therapy with Sofosbuvir and GS-5816
Completed Study; data analyses ongoing
18-80 Years
NIDDK
Liver
15-DK-0108
Natural History of Noncirrhotic Portal Hypertension
Participants currently recruited/enrolled
12-125 Years
NIDDK
Liver
15-DK-0100
A Multidisciplinary Approach to Deciphering the Mechanisms Involved In Microbial Translocation Across the Spectrum of HCV Associated Liver Fibrosis
Completed Study; data analyses ongoing
18-125 Years
NIDDK
Liver
15-DK-0082
Mechanisms Associated with Favorable Response to Peginterferon-Alpha Add-on Therapy Following Long-term Nucleos(t)ide Analogue Treatment in Patients with Chronic Hepatitis B
Completed Study; data analyses ongoing
18-125 Years
NIDDK
Liver
15-DK-0079
Observational Study of Hepatitis B Virus (HBV) in Patients Coinfected with Human Immunodeficiency Virus (HIV)
Completed Study; data analyses ongoing
18-125 Years
NIDDK
Liver
15-DK-0003
Compassionate Use of Metreleptin in Previously-Treated Patients with Generalized Lipodystrophy
Participants currently recruited/enrolled
0-125 Years
NIDDK
Liver
15-DK-0002
Compassionate Use of Metreleptin in Previously-Treated Patients with Partial Lipodystrophy
No longer recruiting/follow-up only
0-125 Years
NIDDK
Liver
15-C-0160
A Phase I Study of Cabozantinib Plus Nivolumab (CaboNivo) Alone or in Combination with Ipilimumab (CaboNivoIpi) in Patients with Advanced/Metastatic Urothelial Carcinoma and other Genitourinary Tumors
No longer recruiting/follow-up only
18-125 Years
NCI
Carcinoma
15-C-0157
Phase I/II Trial of Vandetanib in Combination with Metformin in Subjects with HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma
Completed Study; data analyses ongoing
18-125 Years
NCI
Carcinoma
15-C-0150
A Phase I/II Trial of Topotecan with VX-970 (M6620), an ATR Kinase Inhibitor in Small Cell Cancers
No longer recruiting/follow-up only
18-125 Years
NCI
Carcinoma
15-C-0138
Phase I Study of Ipilimumab, Nivolumab, and the Combination in Patients with Newly Diagnosed Glioblastoma
Completed Study; data analyses ongoing
18-125 Years
NCI
Liver
15-C-0099
A Phase 1, Open-Label, Dose-Escalation Study of SNX-5422 and Everolimus in Subjects with Neuroendocrine Tumors
Completed Study; data analyses ongoing
18-100 Years
NCI
Carcinoma
15-AR-0144
Studies of Dermatologic Diseases-Biospecimen Acquisition Protocol
Participants currently recruited/enrolled
2-125 Years
NIAMS
Carcinoma
14-HG-0071
Clinical and Basic Investigations into Known and Suspected Congenital Disorders of Glycosylation
Participants currently recruited/enrolled
1-80 Years
NHGRI
Liver
14-HG-0055
Study on Moebius Syndrome and Other Congenital Facial Weakness Disorders
Completed Study; data analyses ongoing
2-80 Years
NHGRI
Liver
14-H-0155
A Phase 1/2 Study Evaluating Gene Therapy by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo with the LentiGlobin BB305 Lentiviral Vector in Subjects with Severe Sickle Cell Disease
No longer recruiting/follow-up only
18-50 Years
NHLBI
Liver
14-C-0104
A Phase II Study Using Autologous Young Tumor-Infiltrating Lymphocytes Derived from Patients with Non-Small Cell Lung Cancer Following Non-Myeloablative Lymphocyte Depleting Preparative Regimen
Participants currently recruited/enrolled
18-70 Years
NCI
Carcinoma
14-C-0037
A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer
Completed Study; data analyses ongoing
18-125 Years
NCI
Carcinoma
14-C-0015
Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations
Completed Study; data analyses ongoing
18-125 Years
NCI
Carcinoma
13-I-0062
A Double Blind Randomized Placebo Controlled Study Examining the Effects of a Non-Absorbable (Rifaximin) Antibiotic on the Chronic Immune Activation Observed In HIV-infected Subjects
Completed Study; data analyses ongoing
18-65 Years
NIAID
Liver
13-H-0060
Analysis of Samples Collected from a Subject who Received ACP- 501 (Human Recombinant Lecithin:Cholesterol Acyltransferase [rhLCAT])
Completed Study; data analyses ongoing
18-100 Years
NHLBI
Liver
13-DK-0091
Combination Therapy of Pegylated Interferon Alfa-2a and Tenofovir DF versus Tenofovir DF Monotherapy in HBeAg-Positive and HBeAg-Negative Chronic Hepatitis B
Completed Study; data analyses ongoing
18-125 Years
NIDDK
Liver
13-DK-0057
Short Term Effects of Leptin Withdrawal or Initiation in Lipodystrophy Independent of Energy Intake
Completed Study; data analyses ongoing
14-70 Years
NIDDK
Liver
13-C-0118
A Phase I/II Trial of TRC102 (methoxyamine HCl) in Combination with Temozolomide in Patients with Relapsed Solid Tumors and Lymphomas
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
12-H-0092
An Intravenous, Open-Label, Single-Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of rhLCAT in Patients with Stable Coronary Artery Disease
Completed Study; data analyses ongoing
30-75 Years
NHLBI
Liver
12-DK-0071
Combination Entecavir and Peginterferon Therapy in HBeAg-Positive Immune-Tolerant Adults with Chronic Hepatitis B
Completed Study; data analyses ongoing
18-40 Years
NIDDK
Liver
12-C-0205
A Phase II Study of Cabozantinib (XL184) in Patients With Advanced/Metastatic Urothelial Carcinoma
Completed Study; data analyses ongoing
18-125 Years
NCI
Carcinoma
12-C-0178
Longitudinal Assessment and Natural History Study of Children and Adults with MEN2A or MEN2B with or without Medullary Thyroid Carcinoma
Participants currently recruited/enrolled
0-125 Years
NCI
Carcinoma
12-C-0175
Prospective Procurement of Solid Tumor Tissue to Identify Novel Therapeutic Targets
Completed Study; data analyses ongoing
18-125 Years
NCI
Liver
12-C-0118
A Phase II Study of Sunitinib in Patients with Advanced Relapsed or Refractory Thymoma or Thymic Carcinoma with at Least One Prior Line of Platinum-Based Systemic Chemotherapy
No longer recruiting/follow-up only
18-100 Years
NCI
Carcinoma
11-I-0109
Viral Infections in Healthy and Immunocompromised Hosts
Participants currently recruited/enrolled
0-125 Years
NIAID
Liver
11-DK-0151
Withdrawal of Therapy After Long-Term Oral Nucleos(t)ide Analogue Treatment in Patients with Chronic Hepatitis B
Completed Study; data analyses ongoing
18-125 Years
NIDDK
Liver
11-DK-0108
Observational Study of Persons with Hepatitis B Virus Infection in North America (Cohort Study)
Completed Study; data analyses ongoing
18-100 Years
NIDDK
Liver
11-C-0140
A Phase I Study of Gemcitabine, Carboplatin and Lenalidomide (GCL) for Treatment of Patients with Advanced/Metastatic Urothelial Carcinoma (UC) and Other Solid Tumors
Completed Study; data analyses ongoing
18-125 Years
NCI
Carcinoma
11-C-0112
Acquisition of Blood and Tumor Tissue Samples from Patients with Gastrointestinal Cancer
Participants currently recruited/enrolled
18-125 Years
NCI
Liver
11-C-0096
Pilot Trial of Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies
No longer recruiting/follow-up only
18-125 Years
NCI
Carcinoma
11-C-0061
Phase I Trial of Z-Endoxifen in Adults with Refractory Hormone Receptor-Positive Breast Cancer, Desmoid Tumors, Gynecologic Tumors, or other Hormone Receptor-Positive Solid Tumors
No longer recruiting/follow-up only
18-125 Years
NCI
Liver
10-CC-0217
A Comparison of Methods for Assisting Needle Angle Selection During Image-Guided Tissue Biopsy
Completed Study; data analyses ongoing
18-125 Years
CC
Liver
10-C-0201
Apheresis and CD34+ Selection of Mobilized Peripheral Blood CD34+ Cells from Patients with DOCK8 Deficiency, LAD-1, and GATA2 Deficiency
Participants currently recruited/enrolled
18-40 Years
NCI
Liver
10-C-0166
A Phase II Study Using Short-Term Cultured, Autologous Tumor-Infiltrating Lymphocytes Following a Lymphodepleting Regimen in Metastatic Cancers Plus the Administration of Pembrolizumab
Participants currently recruited/enrolled
18-72 Years
NCI
Carcinoma
10-C-0114
A Phase II Study of Bevacizumab and Erlotinib in Subjects with Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer
Completed Study; data analyses ongoing
18-125 Years
NCI
Carcinoma
09-I-0102
Etiology, Pathogenesis, and Natural History of Idiopathic CD4+ Lymphocytopenia
Participants currently recruited/enrolled
18-125 Years
NIAID
Liver
09-I-0013
Biomarkers of Inflammation, Coagulation, and Endothelial Function in HIV-Infected Adults
Enrolling by Invitation
18-100 Years
NIAID
Liver
09-DK-0097
Vitamin E Pharmacokinetics and Biomarkers in Normal and Obese Women
Completed Study; data analyses ongoing
18-55 Years
NIDDK
Liver
09-C-0161
Follow-Up Protocol for Subjects Previously Enrolled on NCI Surgery Branch Studies
Enrolling by Invitation
18-125 Years
NCI
Carcinoma
08-H-0186
Safety and the Anti- Tumor Effects of Escalating Doses of Adoptively Infused Ex Vivo Expanded Autologous Natural Killer (NK) Cells Against Metastatic Cancers or Hematological Malignancies Sensitized to NK-TRAIL Cytotoxicity with Bortezomib
Completed Study; data analyses ongoing
18-70 Years
NHLBI
Carcinoma
08-DK-0149
High Dose Ribavirin in Combination with Peginterferon for Patients with Chronic Hepatitis C Genotype 1 Infection Who Have Failed to Respond or Relapsed after Standard Therapy
Completed Study; data analyses ongoing
18-65 Years
NIDDK
Liver
08-DK-0098
Natural History of Familial Carcinoid Tumor
Participants currently recruited/enrolled
18-125 Years
NIDDK
Liver
07-C-0121
Phase 2 Study of the C-Met RTK Inhibitor Foretinib (Formerly GSK 1363089) in Subjects with Papillary Renal Cell Carcinoma (PRC)
Completed Study; data analyses ongoing
18-125 Years
NCI
Carcinoma
06-I-0153
A Pilot Study of Hepatic Fibrosis in HIV/AIDS Patients with Chronically Elevated Transaminases on Antiretroviral Therapy
No longer recruiting/follow-up only
18-100 Years
NIAID
Liver
06-H-0217
Genetic Disorders of Mucociliary Clearance
Completed Study; data analyses ongoing
2-65 Years
NHLBI
Liver
06-AR-0198
A Pilot Pediatric/Adult Study of Gene Expression Profiling and Clinical Characterization of Phototoxicity
Completed Study; data analyses ongoing
8-100 Years
NIAMS
Liver
05-H-0130
Long-Term Evaluation and Follow Up Care of Patients Treated with Allogeneic Stem Cell Transplants
Participants currently recruited/enrolled
7-80 Years
NHLBI
Liver
04-HG-0127
Clinical and Basic Investigations of Methylmalonic Acidemia (MMA) and Related Disorders
Participants currently recruited/enrolled
0-125 Years
NHGRI
Liver
04-C-0274
Follow-Up Study of Subjects Previously Enrolled in Immunotherapy Studies Utilizing Gene Transfer or Other Immunotherapeutic Agents
Participants currently recruited/enrolled
18-125 Years
NCI
Liver
03-H-0282
Characterization of Cardiac Function in Subjects with Hereditary Hemochromatosis Who Are New York Heart Association Functional Class I
Completed Study; data analyses ongoing
21-100 Years
NHLBI
Liver
03-C-0066
Hereditary Leiomyomatosis Renal Cell Cancer (HLRCC): Identification of the Disease Gene, and Characterization of the Predisposition to Renal Cancer
Participants currently recruited/enrolled
2-125 Years
NCI
Liver
02-I-0086
Evaluation of Viral Factors and Immune Parameters to Study HIV-Specific Immunity
Participants currently recruited/enrolled
18-125 Years
NIAID
Liver
02-DK-0022
Long-Term Efficacy of Leptin Replacement in Treatment of Lipodystrophy
Completed Study; data analyses ongoing
1-125 Years
NIDDK
Liver
02-CH-0278
Dyadic Interactions in Depressed and Non-Depressed Mothers with Their Infants
Completed Study; data analyses ongoing
0-125 Years
NICHD
Situ
02-C-0313
Cancer Risk in Xeroderma Pigmentosum Heterozygotes
Participants currently recruited/enrolled
0-99 Years
NCI
Carcinoma
02-C-0179
Biospecimen Acquisition from Human Subjects
Participants currently recruited/enrolled
18-125 Years
NCI
Liver
02-C-0064
Collection of Peripheral Blood and/or Urine From Patients Undergoing Radiation Therapy
Enrolling by Invitation
18-125 Years
NCI
Carcinoma
01-I-0238
Host Response to Infection and Treatment in Leishmania Infection of Humans
Participants currently recruited/enrolled
3-100 Years
NIAID
Liver
01-CC-0045
Studies of Phlebotomy Therapy in Hereditary Hemochromatosis
Participants currently recruited/enrolled
18-125 Years
CC
Liver
00-CH-0093
Diagnosis, Pathophysiology, and Molecular Biology of Pheochromocytoma and Paraganglioma
Participants currently recruited/enrolled
3-125 Years
NICHD
Situ
00-C-0078
Collection of Blood, Fluid, Bone Marrow, Tumor, or Tissue Samples from Patients with Cancer or Normal Volunteers
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
95-M-0150
A Neurobiological Investigation of Patients with Schizophrenia Spectrum Disorders and Their Siblings
Participants currently recruited/enrolled
18-55 Years
NIMH
Situ
93-I-0119
Detection and Characterization of Host Defense Defects
Participants currently recruited/enrolled
0-125 Years
NIAID
Liver
93-I-0063
Study of the Immunopathogenesis, Natural History, and Genetics of Autoimmune Lymphoproliferative Syndrome (ALPS) Associated with an Expansion of CD4-8-/TCR alpha/beta+ T Cells
Participants currently recruited/enrolled
0-99 Years
NIAID
Liver
92-I-0125
A Study of Viral Burden in Peripheral Blood Versus Lymphoid and Bone Marrow Tissue in HIV-Infected Individuals
Participants currently recruited/enrolled
18-125 Years
NIAID
Situ
91-I-0140
Studies of the Pathogenesis of HIV Infection in Human Peripheral Blood Cells and/or Body Fluids in HIV-Infected and HIV-Uninfected Volunteers
Participants currently recruited/enrolled
18-125 Years
NIAID
Liver
91-DK-0214
Evaluation of Patients with Liver Disease
Participants currently recruited/enrolled
2-125 Years
NIDDK
Liver
91-CC-0117
Epidemiology, Infectivity and Natural History of Hepatitis C Virus Infection in a Blood Donor Population
No longer recruiting/follow-up only
18-125 Years
CC
Liver
87-DK-0029
Diagnosis and Treatment of Patients with Cystic Fibrosis
Participants currently recruited/enrolled
4-125 Years
NIDDK
Liver
85-H-0105
Cardiovascular Evaluation of Homozygous Familial Hypercholesterolemia
Completed Study; data analyses ongoing
2-70 Years
NHLBI
Liver
83-C-0022
Psychological Benefits of a Normalized Camping Experience for Children with Cancer
Participants currently recruited/enrolled
7-25 Years
NCI
Situ
81-I-0164
Procedures to Obtain Plasma, Lymphocytes, or Other Specimens for Research Studies
Participants currently recruited/enrolled
18-125 Years
NIAID
Liver
79-C-0111
The Treatment of Stage I and II Carcinoma of the Breast with Mastectomy and Axillary Dissection vs. Excisional Biopsy Axillary Dissection, and Definitive Irradiation
Completed Study; data analyses ongoing
18-125 Years
NCI
Carcinoma